Sanofi - American Depositary Shares (NQ:SNY)

39.92 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

42 43 Next >

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials ↗

September 03, 2024

Sanofi's phase 3 HERCULES study data shows tolebrutinib met the primary endpoint in delaying disability progression in non-relapsing secondary progressive multiple sclerosis.

Via Benzinga

European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday? ↗

September 02, 2024

Global markets started September cautiously, with thin trading volumes as U.S. stock markets were closed for the Labor Day holiday.

Via Benzinga

Topics Energy

Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates ↗

August 26, 2024

State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...

Via Benzinga

Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy? ↗

August 24, 2024

Don't be too quick to jump on the Wall Street bandwagon.

Via The Motley Fool

NASDAQ:SNY may be ready to breakout. ↗

August 12, 2024

Will SANOFI-ADR breakout?

Via Chartmill

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗

August 20, 2024

"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...

Via Benzinga

Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell? ↗

August 19, 2024

Its 12-month relative strength performance is impressive, but Novavax now faces resistance.

Via Investor's Business Daily

NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗

August 19, 2024

SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk ↗

August 16, 2024

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...

Via Benzinga

3 Biotech Stocks to Buy on the Dip: August 2024 ↗

August 15, 2024

These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.

Via InvestorPlace

AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering ↗

August 14, 2024

The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.

Via Investor's Business Daily

Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

August 12, 2024

Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.

Via MarketBeat

FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment ↗

August 09, 2024

FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,...

Via Benzinga

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

August 08, 2024

Via Investor Brand Network

COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit ↗

August 08, 2024

Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to...

Via Benzinga

Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant ↗

August 08, 2024

Sanofi's phase 3 GMMG-HD7 study reveals that Sarclisa, combined with lenalidomide, bortezomib, and dexamethasone, significantly prolongs progression-free survival in newly diagnosed multiple myeloma...

Via Benzinga

Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

August 06, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

August 06, 2024

From FN Media Group LLC

Via GlobeNewswire

Where Will Novavax Be in 5 Years? ↗

August 03, 2024

Its been a good year so far for the biotech, but how long can it keep the momentum going?

Via The Motley Fool

Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs ↗

August 01, 2024

Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...

Via Benzinga

JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024 ↗

July 31, 2024

Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets.

Via InvestorPlace

JPMorgan Just Issued a Warning on Novavax (NVAX) Stock ↗

July 30, 2024

Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns.

Via InvestorPlace

Sanofi (SNY) Q2 2024 Earnings Call Transcript ↗

July 25, 2024

SNY earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand ↗

July 25, 2024

Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.

Via Benzinga

25 Best Artificial Intelligence Stocks to Buy Right Now ↗

July 25, 2024

Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.

Via The Motley Fool

Topics Artificial Intelligence

Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday? ↗

July 25, 2024

Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.

Via Benzinga

Topics Economy

American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday ↗

July 25, 2024

Via Benzinga

AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife ↗

July 23, 2024

The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.

Via Benzinga

Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House ↗

July 25, 2024

Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech...

Via Benzinga

Topics Government Stocks

Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally ↗

July 21, 2024

The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.